The IHC photograph (left) demonstrates experimental rabbit CNV prior to breaching Bruch's membrane and the RPE. Also a dilated choroidal blood vessel is shown (in press, Wong CG et al., 2016 Current Eye Research). The second IHC photograph (below left) shows experimental CNV that is anterior to Bruch's membrane. Finally, the third photograph (below right) demonstrates that inflammation is not present in the posterior segment after the implant material was placed subchoroidally to induce experimental CNV.
Patented technologies of SCLERA are helping to solve a $302 billion per year ophthalmic problem in the United States. As a specialized contract research organization, SCLERA evaluates potential back-of-the eye therapeutics for ameliorating retinal diseases. By utilizing its ocular implants that produce retinal diseases simulating either diabetic retinopathy or wet age-related macular degeneration (AMD) in the rabbit eye, SCLERA has served some of the largest international pharmaceutical companies (i.e. Allergan, Alcon, Bausch & Lomb) for pre-clinical evaluation of potential retinal therapeutics.
Why use the rabbit eye? Choroidal neovascularization (CNV) is the major cause of "wet" AMD in the aging eye. Laser-induced monkey and rodent CNV already have been produced. However, the rabbit eye does not produce CNV with the standard laser treatment. More importantly, the rabbit can tolerate administrations of monoclonal antibodies unlike rodent eyes. For over 30 years, many research laboratories and international companies have attempted to produce rabbit CNV without success. SCLERA has produced experimental CNV successfully in the rabbit by mechanistic use of growth factors.
Contact us: +1 760 505-1019
SCLERA LLC 6965 El Camino Real, Suite 105, Carlsbad CA USA +1 (760) 505-1019 Accelerating the Discovery of Novel Ophthalmic Drugs
To Improve, Invent, and Innovate